Published Date: 16 Mar 2023
In Part 1 of the Obesity Series, Katherine H. Saunders, MD, DABOM discusses ways to treat childhood obesity, including the benefits of FDA-approved drugs and Intellihealth.
Read Full NewsNovartis plans to submit regulatory applications for ianalumab in early 2026.
Pulmonary arterial hypertension treatment continues to evolve with new therapies and strategies.
If approved, lecanemab-irmb would provide an at-home subcutaneous injection option for both treatment initiation and maintenance dosing for patients with early-stage Alzheimer disease.
A recent study linked maternal diabetes to a doubled risk of multiple sclerosis in offspring, highlighting prenatal factors in MS susceptibility.
Head-to-head PET imaging data indicated that valbenazine achieves significantly higher VMAT2 target occupancy than deutetrabenazine XR at therapeutic doses, with both treatments remaining well tolerated.
The FDA raised no objections to Lexicon Pharmaceuticals’ pilavapadin for a phase 3 program, which will include 2-arm registrational studies, in patients with diabetic peripheral neuropathic pain.
McGill emphasizes new exciting data shared at ACR 2025.
1.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
2.
We Don't Always Know What's 'Best' for Our Patients
3.
AI is useful in low-resource areas for triaging breast masses.
4.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
5.
Improved end-of-life conversations for cancer patients are identified by a new study.
1.
Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression
2.
Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post
3.
Building Bridges between Heart and Cancer Care: A Comprehensive Guide to Cardio-Oncology Clinics
4.
Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights
5.
From Autoimmune Disorders to COVID-19: How Plasmapheresis Is Revolutionizing Modern Medicine
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation